{"schema_version":"secwatch.filing_event.v1","accession":"0000944809-22-000023","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.517919+00:00","generated_at":"2026-06-25T22:48:39.285992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale","bullets":["Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.","Diagnostics revenue $286.6M (down from $507.0M) due to lower COVID-19 testing: 2.0M tests vs 4.1M YoY.","Acquired ModeX Therapeutics for $300M in OPKO common stock; Dr. Elias Zerhouni named President and Vice Chairman.","Closed sale of GeneDx to Sema4 for ~$322M upfront (cash + stock) plus up to $150M in milestones.","Pfizer launched NGENLA in Germany/Japan; OPKO earned $85M milestones. RAYALDEE launched in Germany by Vifor."],"urls":{"canonical":"https://secwatch.observer/filing/0000944809-22-000023","json":"https://secwatch.observer/filing/0000944809-22-000023.json","markdown":"https://secwatch.observer/filing/0000944809-22-000023.md","text":"https://secwatch.observer/filing/0000944809-22-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/0000944809-22-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/opk-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:48:39.285992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}